07:00 , Apr 6, 2015 |  BC Week In Review  |  Company News

Catamaran, UnitedHealth Group other news

The OptumRx Inc. pharmacy benefit manager unit of UnitedHealth will acquire fellow PBM Catamaran for $61.50 per share in cash, or $12.8 billion. The price is a 27% premium to Catamaran’s close of $48.32 on...
01:06 , Mar 31, 2015 |  BC Extra  |  Company News

OptumRx acquires Catamaran, consolidating PBMs

OptumRx Inc., the pharmacy benefit manager unit of UnitedHealth Group Inc. (NYSE:UNH), will acquire Catamaran Corp. (NASDAQ:CTRX; TSX:CCT) for $61.50 per share, or $12.8 billion in cash. The combined company expects to fulfill about 1...
07:00 , Mar 16, 2015 |  BioCentury  |  Strategy

Zarxio tea leaves

As the first approved U.S. biosimilar, Zarxio filgrastim-sndz from Novartis AG's Sandoz unit will give a glimpse at the discount size for biosimilars and how the innovator company responds to the competition. But questions about...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Company News

Gilead, Catamaran, Cigna Corp. sales and marketing update

Catamaran selected Gilead’s Harvoni ledipasvir/sofosbuvir and Sovaldi sofosbuvir as an exclusive therapy for HCV infections for both its national and value formularies and Cigna selected Harvoni as its preferred prescription to treat HCV genotype 1...
02:24 , Feb 5, 2015 |  BC Extra  |  Company News

HCV stocks fall after Gilead's discount signal

HCV stocks took a hit on Wednesday after Gilead Sciences Inc. (NASDAQ:GILD) said it will provide larger discounts in 2015 than investors were anticipating on its Harvoni ledipasvir / sofosbuvir and Sovaldi sofosbuvir. The disclosure...
08:00 , Jan 19, 2015 |  BioCentury  |  Strategy

Partitioning HCV

Gilead Sciences Inc. and AbbVie Inc. continue to vie for preferred coverage of their HCV drugs in the U.S. private payer market, and Gilead is out to an early lead when it comes to total...
07:00 , Sep 1, 2014 |  BioCentury  |  Strategy

Back to School: Paying the piper

Pharma has lost its pricing power in many countries, as evidenced by reimbursement authorities' willingness to delay or outright deny access to drugs whose costs are deemed unacceptable. Now, the availability of a costly drug...
07:00 , Jun 9, 2014 |  BioCentury  |  Strategy

Guest Commentary: Cost steamroller

At a private meeting for payers and policy makers the other week, the CMO of one of the big PBMs noted that if Gilead Sciences Inc. 's transformational, and transformationally priced, HCV drug Sovaldi sofosbuvir...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

Tesaro management update

Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass.   Business: Cancer   Hired: Tim Pearson as CFO, formerly EVP and CFO of Catalyst Health Solutions Inc. , which merged with SXC Health Solutions Corp. to form Catamaran Corp....
07:00 , May 26, 2014 |  BioCentury  |  Strategy

Measured exclusion

At a time when some PBMs are cracking down on mounting specialty drug costs through tools like excluded drugs lists, Catamaran Corp. is taking a more measured approach. The excluded drugs list the PBM plans...